Background illustration for clinical trials search

Paid Clinical Trials Eugene

Discover 156 paid clinical trials in Eugene, Oregon. Search by condition or phase to find a research study near you that matches your needs across various therapeutic areas.

Filter
2

A Study of Amivantamab in Combination With Lazertinib, or Amivantamab in Combination With Platinum-Based Chemotherapy, for Common Epidermal Growth Factor Receptor (EGFR)-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)

for
Carcinoma, Non-Small-Cell Lung
Location: Eugene OR, Portland OR, Olympia WA, Spokane WA,
Sponsor: Janssen Research & Development, LLC

Sex: All

Age: 18+

Code: NCT06667076

Phase 2, Recruiting

Study of NX-5948 in Combination With Other Agents in Adults With B-cell Malignancies

for
B-cell Lymphoma, Chronic Lymphocytic Leukemia,
Location: Eugene OR, Aurora CO, Nashville TN
Sponsor: Nurix Therapeutics, Inc.

Sex: All

Age: 18+

Code: NCT07520006

Phase 1, Phase 2, Recruiting

A Study of Elranatamab Outpatient Administration in Patients With Relapsed/Refractory Multiple Myeloma

for
Multiple Myeloma (MM), Multiple Myeloma Refractory,
Location: Eugene OR, Las Vegas NV, Denver CO, Nashville TN,
Sponsor: SCRI Development Innovations, LLC

Sex: All

Age: 18+

Code: NCT07637578

Phase 2, Recruiting

BGB-43395 Plus Letrozole Versus CDK4/6i Plus Letrozole for Patients With Advanced or Metastatic HR+/HER2- Breast Cancer Who Have Not Received Prior Treatment for Advanced or Metastatic Disease

for
HR+/HER2- Breast Cancer
Location: Eugene OR, Salem OR, Olympia WA, Yakima WA, Tacoma WA,
Sponsor: BeOne Medicines

Sex: All

Age: 18+

Code: NCT07492641

Phase 3, Recruiting

A Study Comparing JNJ-79635322 and Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma

for
Multiple Myeloma
Location: Eugene OR, Tacoma WA, Salt Lake City UT, Calgary,
Sponsor: Janssen Research & Development, LLC

Sex: All

Age: 18+

Code: NCT07518186

Phase 3, Recruiting

Interested in new trials?

Get alerts for new trials in your area by subscribing now

Subscriber Image

Symbiotic-GU-06: A Study to Learn About PF-08634404 Alone or In Combination With Enfortumab Vedotin in Urothelial Cancer

for
Urothelial Cancer, Advanced/Metastatic Urothelial Cancer,
Location: Eugene OR, Springfield OR, Tigard OR, Portland OR,
Sponsor: Pfizer

Sex: All

Age: 18+

Code: NCT07421700

Phase 1, Phase 2, Recruiting

A Study to Evaluate Pumitamig Versus Durvalumab Following Concurrent Chemoradiation Therapy in Participants With Unresectable Stage III Non-small Cell Lung Cancer (NSCLC) (ROSETTA Lung-201)

for
Non-small Cell Lung Cancer (NSCLC)
Location: Eugene OR, Happy Valley OR, Golden CO, Amarillo TX,
Sponsor: Bristol-Myers Squibb

Sex: All

Age: 18+

Code: NCT07361497

Phase 3, Recruiting

A Study to Investigate Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Acalabrutinib in Adults With Previously Untreated Chronic Lymphocytic Leukemia

for
Chronic Lymphocytic Leukemia
Location: Eugene OR, Seattle WA, Victoria, Palo Alto CA,
Sponsor: BeOne Medicines

Sex: All

Age: 18+

Code: NCT07277231

Phase 3, Recruiting

A Study to Evaluate the Safety and Efficacy of Pumitamig in Combination With Chemotherapy Versus Nivolumab in Combination With Chemotherapy in Participants With Previously Untreated Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma (ROSETTA Gastric-204)

for
Untreated Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma,
Location: Eugene OR, Portland OR, Los Angeles CA, Orange CA,
Sponsor: Bristol-Myers Squibb

Sex: All

Age: 18+

Code: NCT07221149

Phase 2, Phase 3, Recruiting

Study of NXP900 With Osimertinib in Subjects With Advanced, EGFR-Mutated Non-Small Cell Lung Cancer

for
EGFR Mutation Positive Non-small Cell Lung Cancer,
Location: Eugene OR, Houston TX, Pittsburgh PA, Fairfax VA,
Sponsor: Nuvectis Pharma, Inc.

Sex: All

Age: 18+

Code: NCT07315113

Phase 1, Recruiting

A Study of Tersolisib (LY4064809/STX-478) With Other Anti-Cancer Treatments in Participants With Advanced Breast Cancer With a Genetic Change (PIK3CA)

for
Breast Neoplasms, Neoplasm Metastasis
Location: Eugene OR, Corvallis OR, Yakima WA, Tacoma WA,
Sponsor: Eli Lilly and Company

Sex: All

Age: 18+

Code: NCT07174336

Phase 3, Recruiting

Study to Assess the Efficacy and Safety of Rina-S Compared to Treatment of Investigator's Choice in Participants With Endometrial Cancer

for
Endometrial Cancer, Recurrent or Progressive Endometrial Cancer
Location: Eugene OR, Tigard OR, Happy Valley OR, Portland OR,
Sponsor: Genmab

Sex: Female

Age: 18+

Code: NCT07166094

Phase 3, Recruiting

A Three-Part Phase 3 Study of Sofetabart Mipitecan in Participants With Platinum-Resistant (Part A) and Platinum-Sensitive (Parts B and C) Ovarian Cancer

for
Ovarian Neoplasms, Fallopian Tube Neoplasms,
Location: Eugene OR, Portland OR, Seattle WA, Edmonds WA, Reno NV,
Sponsor: Eli Lilly and Company

Sex: All

Age: 18+

Code: NCT07213804

Phase 3, Recruiting

A Clinical Study of Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) as First-line Maintenance Treatment of Cervical Cancer (MK-2870-036/TroFuse-036/GOG-3123/ENGOT-cx22)

for
Cervical Cancer
Location: Eugene OR, Calgary, Las Vegas NV, Orange CA, Irvine CA,
Sponsor: Merck Sharp & Dohme LLC

Sex: Female

Age: 18+

Code: NCT07216703

Phase 3, Recruiting

Studies to Assess Ziftomenib in Combination With Ven+Aza or 7+3 in Patients With Untreated NPM1-m or KMT2A-r AML

for
Acute Myeloid Leukemia (AML)
Location: Eugene OR, Vancouver, Clovis CA, Los Angeles CA,
Sponsor: Kura Oncology, Inc.

Sex: All

Age: 18+

Code: NCT07007312

Phase 3, Recruiting

A Study of Tacabrutideg (BGB-16673) Compared to Investigator's Choice in Participants With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Previously Exposed to Both Bruton Tyrosine Kinase (BTK) and B-cell Leukemia/Lymphoma 2 Protein (BCL2) Inhibitors

for
CLL, Chronic Lymphocytic Leukemia
Location: Eugene OR, Billings MT, Los Angeles CA, Whittier CA,
Sponsor: BeOne Medicines

Sex: All

Age: 18+

Code: NCT06846671

Phase 3, Recruiting

Enfortumab Vedotin in Combination With Pembrolizumab vs. Concurrent Chemoradiotherapy (cCRT) in People With Muscle Invasive Bladder Cancer (EV-309)

for
Urothelial Cancer, Urinary Bladder Neoplasms
Location: Eugene OR, Tigard OR, Santa Barbara CA, Aurora CO,
Sponsor: Astellas Pharma Global Development, Inc.

Sex: All

Age: 18+

Code: NCT07566156

Phase 3, Recruiting

A Study of Izalontamab Brengitecan Versus Chemotherapy in Participants With Previously Untreated, Locally Advanced, Recurrent Inoperable, or Metastatic Triple-negative Breast Cancer Ineligible for Anti-PD(L)1 Drugs (IZABRIGHT-Breast01)

for
Breast Neoplasms
Location: Eugene OR, Kelowna, Los Angeles CA, Cerritos CA,
Sponsor: Bristol-Myers Squibb

Sex: All

Age: 18+

Code: NCT06926868

Phase 2, Phase 3, Recruiting

A Study to Investigate Progression-Free Survival With Sonrotoclax Plus Obinutuzumab Or Sonrotoclax Plus Rituximab Compared With Venetoclax Plus Rituximab Treatment In Patients With Relapsed and/or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CELESTIAL-RRCLL)

for
Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
Location: Eugene OR, Vancouver WA, Seattle WA, Vancouver,
Sponsor: BeOne Medicines

Sex: All

Age: 18+

Code: NCT06943872

Phase 3, Recruiting

A Study of Fruquintinib Plus FOLFIRI as Second-Line Treatment for Participants With Metastatic Colorectal Cancer (FRUITFUL)

for
Colon Cancer, Rectal Cancer, Colorectal Cancer,
Location: Eugene OR, Portland OR, Denver CO, Maple Grove MN,
Sponsor: SCRI Development Innovations, LLC

Sex: All

Age: 18+

Code: NCT07011576

Phase 2, Recruiting